Countries Taking Action to Strengthen API Supply Chains

The Perception of "APIs as Strategic Assets" Is the Driving Force

APIs Should Be Recognized as a Pillar of the Materials, Parts, and Equipment Industry

Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

Have you ever been unable to take your medication on time due to a lack of medicine? South Korea is one of the few countries in the world capable of producing more than 70% of the pharmaceuticals needed for disease treatment domestically. Thanks to this, citizens are able to go about their daily lives with relatively little inconvenience. However, we cannot afford to be complacent. The supply system for active pharmaceutical ingredients (APIs), the starting point of pharmaceutical production, is now under threat.


Since 2000, the domestic self-sufficiency rate for APIs has repeatedly fluctuated around 30%, but in 2022, it plummeted to just 11.9%. In particular, the domestic self-sufficiency rate for penicillin antibiotic APIs stands at 0%, and for cephalosporin antibiotic APIs is only about 30%. This is because there is a high dependence on cheap imported APIs from countries such as China and India. While using inexpensive APIs may be considered a rational economic choice, this is no longer the case when global supply chains are disrupted by infectious disease outbreaks or geopolitical conflicts. Without securing the necessary raw materials, production facilities are rendered useless. Antibiotics are essential medicines for responding to infectious diseases, so any disruption in their supply during a pandemic—such as we experienced with COVID-19—could result in catastrophic consequences. The pharmaceutical supply chain is therefore a matter of national health security.


Supply chain disruptions during a pandemic can be fatal


For this reason, after COVID-19, major countries around the world have taken active steps to strengthen supply chains. The Austrian government, for example, has provided subsidies amounting to about 50 million euros (approximately 7.76 billion won) to support the stable production of antibiotics at the Sandoz production plant in Austria. Likewise, Japan has allocated government funds to restart domestic production of penicillin antibiotic APIs, which had been entirely reliant on imports. India operates a Production Linked Incentive (PLI) system, offering incentives of a certain percentage of increased local manufacturing sales to promote domestic manufacturing such as the pharmaceutical industry. From 2021, India has designated APIs, starting materials, and pharmaceutical intermediates as key targets, allocating a total budget of 69.4 billion rupees (about 1.11 trillion won) over ten years. These efforts demonstrate that governments are recognizing APIs as strategic assets for health security and are actively providing support.

Reference image generated by AI

Reference image generated by AI

View original image

The South Korean government has also extended preferential pricing periods for pharmaceuticals that use domestically produced APIs and expanded the scope to include not only new medicines but also existing products. This is known as the "direct production API price addition system." However, its scope is limited, as it is restricted to essential medicines—only 491 items—and only pharmaceutical companies that directly produce APIs can receive support. Many domestic pharmaceutical and biotech companies, considering the expertise required for the final product and APIs and the economic efficiency of scale, have established API subsidiaries or affiliates to operate more efficiently. Therefore, to achieve the original intent of "stabilizing the API supply," this policy should also recognize domestic production through subsidiaries and affiliates as within the scope of support.


Health security policy is essential for stabilizing the production base


Above all, strengthening the API supply chain faces structural limitations if approached solely through insurance pricing policies. Since pharmaceutical pricing policy must also take into account the sustainability of the insurance budget, there are limits to how stably it can support domestic API production bases and improve industrial competitiveness. Therefore, separate from insurance pricing policy, health security strategies are needed to stabilize and expand the domestic API production base. From this perspective, APIs should be viewed as a key pillar of the nation's materials, parts, and equipment (so-bu-jang) industry, and efforts must be made to secure domestic production capacity for essential and core APIs. At the same time, it is necessary to shift thinking and foster global competitiveness by developing and producing high value-added APIs for export to the world market. I propose establishing a new strategy that both strengthens health security domestically and expands exports to enhance the competitiveness of the industry.



Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing